To further complement this monitoring approach, we measured DNA-based BCR::ABL1 fusion gene and RNA-based transcript levels in parallel in 64 pediatric CML patients during their treatment. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.